The regimen being tested in this study is the combination of ixazomib, daratumumab, and dexamethasone. This study will look at the efficacy and safety of Ixazomib + Daratumumab + Dexamethasone (IDd) in people who have relapsed and/or refractory multiple myeloma (RRMM). The study will enroll approximately 60 patients.
Participants will be assigned to the treatment group:
This multi-center trial will be conducted worldwide. The overall time to participate in this study is 5 years. Participants will make multiple visits to the clinic, and every 12 weeks after progressive disease until death or termination of the study by the sponsor.
The following criteria is a partial list of reasons why patients may or may not be eligible to participate in this clinical trial. Further evaluation with a medical professional will be required to determine full eligibility.
The following criteria is provided for health care professionals.